Alfacell Corporation Launches New Investor Relations Section of Company Website

Alfacell Corporation(Nasdaq: ACEL), a biopharmaceutical company focused on the discovery,development and commercialization of novel ribonuclease (RNase) therapeuticsfor cancer and other life-threatening diseases, today announced that theCompany has upgraded its current website at http://www.alfacell.com. While some graphical modifications were made to the entire website,efforts to enhance the existing site were focused on the Investor Relationssection. Many new features and components have been added to allow visitorsaccess to a broader range of historical and contemporary data, and provides anew suite of tools to research and request information. "We would like to invite all of our shareholders, industry observersfollowing our clinical programs, and others interested in our Company to visitour upgraded website," said Kuslima Shogen, Chairman and CEO of Alfacell. About Alfacell Corporation Alfacell Corporation is a biopharmaceutical company focused on thediscovery, development and commercialization of novel therapeutics for cancer,using its proprietary RNase technology platform. ONCONASE(R) (ranpirnase),Alfacell's lead investigational drug candidate, is currently being evaluatedin several studies, including a Phase IIIb registration study for malignantmesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer(NSCLC). For more information, please visit http://www.alfacell.com. This press release includes statements that may constitute"forward-looking" statements, usually containing the words "believe,""estimate," "project," "expect" or similar expressions. Forward-lookingstatements involve risks and uncertainties that could cause actual results todiffer materially from the forward-looking statements. Factors that wouldcause or contribute to such differences include, but are not limited to,uncertainties involved in transitioning from concept to product, uncertaintiesinvolving the ability of the Company to finance research and developmentactivities, potential challenges to or violations of patents, uncertaintiesregarding the outcome of clinical trials, the Company's ability to securenecessary approvals from regulatory agencies, dependence upon third-partyvendors, and other risks discussed in the Company's periodic filings with theSecurities and Exchange Commission. By making these forward-lookingstatements, the Company undertakes no obligation to update these statementsfor revisions or changes after the date of this release.